Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jonathan Harris

Showing results (101-110 of 129) with videos related to

Pageof 13
Sort By:
JAMA Network Open|June 2, 2023
Long-term Outcomes of Bevacizumab and Chemoradiation for Locoregionally Advanced Nasopharyngeal Carcinoma: A Nonrandomized Controlled TrialNancy Y Lee, Jonathan Harris, John Kim, et al.
International Journal of Radiation Oncology, Biology, Physics|March 16, 2023
Final Report of NRG Oncology RTOG 0022: A Phase 1/2 Study of Conformal and Intensity Modulated Radiation for Oropharyngeal CancerAdam S Garden, Jonathan Harris, Avraham Eisbruch, et al.
Oral Oncology|February 28, 2021
Risk groups of laryngeal cancer treated with chemoradiation according to nomogram scores - A pooled analysis of RTOG 0129 and 0522Musaddiq J Awan, Haley Gittleman, Jill Barnholtz-Sloan, et al.
Cancers|July 2, 2021
NRG-HN003: Phase I and Expansion Cohort Study of Adjuvant Pembrolizumab, Cisplatin and Radiation Therapy in Pathologically High-Risk Head and Neck CancerJulie E Bauman, Jonathan Harris, Ravindra Uppaluri, et al.
Cancer|October 5, 2020
Predictive classifier for intensive treatment of head and neck cancerKaveh Zakeri, Federico Rotolo, Benjamin Lacas, et al.
Cancer|July 16, 2016
Establishing quality indicators for neck dissection: Correlating the number of lymph nodes with oncologic outcomes (NRG Oncology RTOG 9501 and RTOG 0234)Vasu Divi, Jonathan Harris, Paul M Harari, et al.
Cancer|March 27, 2019
Validation of NRG oncology/RTOG-0129 risk groups for HPV-positive and HPV-negative oropharyngeal squamous cell cancer: Implications for risk-based therapeutic intensity trialsCarole Fakhry, Qiang Zhang, Maura L Gillison, et al.
International Journal of Radiation Oncology, Biology, Physics|March 13, 2026
Quality of life in patients with p16+ oropharyngeal cancer receiving accelerated radiotherapy with either cisplatin or cetuximab in the NRG/RTOG 1016 randomized controlled trialJolie Ringash, Pedro A Torres-Saavedra, Maura L Gillison, et al.
Cancer Research Communications|March 6, 2026
The KRAS-variant and cetuximab in HPV-positive oropharyngeal cancer - results from the NRG/RTOG 1016 trialJoanne B Weidhaas, Jonathan Harris, Maura L Gillison, et al.
JAMA Oncology|March 30, 2023
Pathologic Complete Response and Clinical Outcomes in Patients With Localized Soft Tissue Sarcoma Treated With Neoadjuvant Chemoradiotherapy or Radiotherapy: The NRG/RTOG 9514 and 0630 Nonrandomized Clinical TrialsDian Wang, Jonathan Harris, William G Kraybill, et al.
Pageof 13

Showing results (101-110 of 129) with videos related to

Sort By:
Pageof 13
JAMA Network Open|June 2, 2023
Long-term Outcomes of Bevacizumab and Chemoradiation for Locoregionally Advanced Nasopharyngeal Carcinoma: A Nonrandomized Controlled TrialNancy Y Lee, Jonathan Harris, John Kim, et al.
International Journal of Radiation Oncology, Biology, Physics|March 16, 2023
Final Report of NRG Oncology RTOG 0022: A Phase 1/2 Study of Conformal and Intensity Modulated Radiation for Oropharyngeal CancerAdam S Garden, Jonathan Harris, Avraham Eisbruch, et al.
Oral Oncology|February 28, 2021
Risk groups of laryngeal cancer treated with chemoradiation according to nomogram scores - A pooled analysis of RTOG 0129 and 0522Musaddiq J Awan, Haley Gittleman, Jill Barnholtz-Sloan, et al.
Cancers|July 2, 2021
NRG-HN003: Phase I and Expansion Cohort Study of Adjuvant Pembrolizumab, Cisplatin and Radiation Therapy in Pathologically High-Risk Head and Neck CancerJulie E Bauman, Jonathan Harris, Ravindra Uppaluri, et al.
Cancer|October 5, 2020
Predictive classifier for intensive treatment of head and neck cancerKaveh Zakeri, Federico Rotolo, Benjamin Lacas, et al.
Cancer|July 16, 2016
Establishing quality indicators for neck dissection: Correlating the number of lymph nodes with oncologic outcomes (NRG Oncology RTOG 9501 and RTOG 0234)Vasu Divi, Jonathan Harris, Paul M Harari, et al.
Cancer|March 27, 2019
Validation of NRG oncology/RTOG-0129 risk groups for HPV-positive and HPV-negative oropharyngeal squamous cell cancer: Implications for risk-based therapeutic intensity trialsCarole Fakhry, Qiang Zhang, Maura L Gillison, et al.
International Journal of Radiation Oncology, Biology, Physics|March 13, 2026
Quality of life in patients with p16+ oropharyngeal cancer receiving accelerated radiotherapy with either cisplatin or cetuximab in the NRG/RTOG 1016 randomized controlled trialJolie Ringash, Pedro A Torres-Saavedra, Maura L Gillison, et al.
Cancer Research Communications|March 6, 2026
The KRAS-variant and cetuximab in HPV-positive oropharyngeal cancer - results from the NRG/RTOG 1016 trialJoanne B Weidhaas, Jonathan Harris, Maura L Gillison, et al.
JAMA Oncology|March 30, 2023
Pathologic Complete Response and Clinical Outcomes in Patients With Localized Soft Tissue Sarcoma Treated With Neoadjuvant Chemoradiotherapy or Radiotherapy: The NRG/RTOG 9514 and 0630 Nonrandomized Clinical TrialsDian Wang, Jonathan Harris, William G Kraybill, et al.
Pageof 13